Cibus Updates Business Outlook in 8-K, Projects >$200M Annual Royalties from Rice Traits

Cibus, Inc.

Cibus estimates over $200 million potential annual addressable royalties from Rice herbicide tolerance traits in the US and Latin America.
Company reduced workforce by approximately 34 full-time employees by December 31, 2025, to streamline focus on Rice program.
Anticipates annual net cash usage of $30 million or less during 2026 following cost reduction actions.
Biofragrance products program could reach $20-40 million annual revenue over a long-term horizon, with initial payments received in 2025.
EU trilogue on New Genomic Techniques positively concluded in December 2025, creating a regulatory path for gene-edited plants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.